This also applies to more recent clinical trials examining cardiovascular treatment effects in patients with CKD, including the trials with sodium-glucose cotransporter-2 (SGLT2) inhibitors (canagliflozin in the CREDENCE trial [15]; dapagliflozin in the DAPA-CKD trial [16]), glucagon-like peptide-1 (GLP-1) receptor agonists (liraglutide in the LEADER trial [17]), and nonsteroidal mineralocorticoid receptor antagonists (finerenone in the FIDELIO-DKD and FIGARO-DKD trials [18, 19]). Here, NR3C2 is linked to chronic kidney disease.